For the fiscal quarter ending June 30, 2026, Palatin Technologies is expected to report a consensus revenue of $1.50 million and a net loss of $1.20 per share, with the stock currently trading around $10.48 against an aggressive average analyst price target of $53.50.
Investors are primarily focused on clinical updates regarding Palatin’s lead obesity candidate, PL7737, an oral melanocortin-4 receptor agonist that is transitioning into Phase 1 clinical trials.
Recent financial results have shown a significant narrowing of net losses due to disciplined cost management and a strategic shift toward obesity therapeutics following the sub-licensing of its dry eye disease asset. The company’s balance sheet has been recently bolstered by public offerings and milestone payments from its retinal disease collaboration with Boehringer Ingelheim, which remains a key component of its long-term cash runway.